Cachexia and muscle wasting are recognized as being the consequence of aging and many illnesses and affect millions of elderly people and patients \[[@CR1]--[@CR3]\]. Both are closely associated with poor quality of life as well as significantly increased morbidity and mortality \[[@CR4]\]. In the last decades, no therapies have been approved for muscle wasting or cachexia, but significant efforts are made by many researchers as well as numerous pharmaceutical companies \[[@CR5], [@CR6]\]. Therapeutic efforts involve for instances substances that are active in the ghrelin---growth hormone---insulin-like growth factor-1 pathway, specific androgen receptor modulators (SARMs), or drugs that interfere with myostatin and activin receptors. Also, novel types of beta-blockers and anti-inflammatory compounds are in clinical testing.

An important aspect of research in any new field of therapeutic development is a common language for medical science and communication as well as for exchange with regulatory authorities. Despite several efforts to develop consensus definitions for cachexia \[[@CR7], [@CR8]\] or sarcopenia \[[@CR9]--[@CR11]\], and to develop new terms for muscle wasting (like myopenia) \[[@CR12]\], a common conceptual approach and vocabulary has not yet been established. This approach should encompass all relevant types of cachexia as well as sarcopenia, and it should be universally applicable in medicine.

Over the years, we have recognized that the term "cachexia"---although understood in all languages---is somewhat suboptimal as clearly some patients with clinically important tissue wasting do not have weight loss (or even have weight gain), and, hence, they do not suffer from cachexia. Regarding the term "sarcopenia," there is no consensus whether it should be used narrowly only for aging-associated muscle wasting alone or more broadly for any muscle wasting in any illness. The term "myopenia" was suggested \[[@CR12]\] in order to introduce a term that can describe muscle wasting in any chronic illness and to have a term that unlike "muscle wasting" is easily understood in any language.

During the recent 7th Cachexia Conference in Kobe, Japan which was organized in December 2013 \[[@CR13]\], discussions on this issue of a common nomenclature continued. It is clear that a common nomenclature is needed to promote treatment development efforts. In the discussions, we have come to understand that for the time being, a focus on the English language for such a common nomenclature may seem appropriate as all major research discussions and publications, all international medical education efforts, as well as all international industry and regulatory discussions take place in English language. If we drop the requirement that a common disease definition term for now does not need to be translatable in many languages, then using the term "muscle wasting" will appear much more attractive.

If the above is accepted and if we also recognize that muscle wasting is the one common process in all cachexia and in sarcopenia, then we may consider all these different diseases as "muscle wasting diseases." In this paper, we would like to outline a brief proposal for such a disease classification of *muscle wasting diseases* (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Framework for the suggested classification of muscle wasting disease by disease etiology and disease progression

The proposal distinguishes between muscle wasting disease (MWD) in an acute and a chronic disease setting. The latter is the most frequent form of MWD and can be classified by its etiology (i.e., that they are due to an underlying chronic illness or aging, which is then termed sarcopenia) and by disease severity or progression. We propose that the latter also includes what is known as pre-cachexia as well as any form of cachexia (Fig. [1](#Fig1){ref-type="fig"}).

The suggested approach brings together the concepts of muscle wasting, sarcopenia, frailty, and cachexia. It allows the application of this concept in acute and chronic disease settings, and it is pertinent for wasting disease of any severity and due to any underlying illness. The concept of muscle wasting disease is based on the most common denominator of the underlying wasting processes, i.e., muscle wasting, without ignoring advanced disease states that are also accompanied by fat tissue wasting. Lastly, the term *muscle wasting disease* is easily understood by the scientific community as well as the lay public, which may promote its general use. The term makes no assumption about a particular pathophysiology of the disease process, and we think it is useable in all degrees of wasting disorders. The term muscle wasting disease is not fully translatable in all important languages, but we hope this shortcoming is of limited importance for scientific, treatment development, as well as regulatory discussions and possibly also in consultations with reimbursement authorities.

Further refinement of the concept of muscle wasting disease may be desirable, and we hope that this can be achieved in discussions with all stakeholders in the next year. Meetings to this end will be organized by the Society on Sarcopenia, Cachexia and Wasting Disorders. Please see [www.scwd.org](http://www.scwd.org/) for more information and contact us directly, if you are interested in participating in such deliberations.
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